A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation - INCB 99280-204

Incyte Corp.0 个研究点目标入组 125 人开始时间: 2023年11月16日最近更新: 2024年7月22日

适应症

试验速览

阶段: 1 期
状态: 招募中
发起方: Incyte Corp.
入组人数: 125

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 65+（—）
性别: All

入选标准

•Ability to comprehend the participant information and willingness to sign a written ICF for the study., ECOG performance status of 0 or 1., Estimated life expectancy > 3 months., Willingness to avoid pregnancy or fathering children based on the criteria below. a.Men must agree to take appropriate precautions to avoid fathering children (with at least 99% certainty) from screening through 100 days after the last dose of study drug (or longer as appropriate based on country-specific requirements) and must refrain from donating sperm during this period. Permitted methods that are at least 99% effective in preventing pregnancy (see Appendix A) should be communicated to the participants and their understanding confirmed. b.Women of childbearing potential must do the following: ?Have a negative serum pregnancy test at screening and must agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through 190 days after the last dose of study treatment. Permitted methods that are at least 99% effective in preventing pregnancy (see Appendix A) should be communicated to the participants and their understanding confirmed. ?Refrain from donating oocytes from 30 days before the first dose of study drug until 90 days after the last dose. c.Women of nonchildbearing potential (ie, surgically sterile with a hysterectomy and/or bilateral oophorectomy OR = 12 months of amenorrhea and at least 50 years of age) are eligible., Men and women 18 years of age or older at the time of signing the ICF., KRASG12C-mutated solid malignancy determined by a sponsor-approved assay using either tumor tissue or ctDNA., Histologically confirmed malignant solid tumor with locally advanced and/or metastatic disease. a.Only participants with NSCLC will be enrolled into Part 2 Cohort A. b.Only participants with CRC will be enrolled into Part 2 Cohort B., Part 1: Disease progression on or after at least 1 prior systemic treatment. Participants must have received all available local standard of care therapies., Part 2 (Cohort A): Received at least 1 platinum-containing chemotherapy regimen that may include an anti–PD-1 inhibitor., Part 2 (Cohort B): Received at least 1 line of systemic therapy., Measurable disease according to RECIST v1.1., Known PD-L1 expression level in tumor. The PD-L1 expression level may have been determined at any point in the disease course using a commercially available assay or can be tested locally during the screening process (using a commercially available assay) and the results reported to the sponsor. If PD-L1 expression is unknown or cannot be tested locally, participants must be willing to provide tumor tissue (fresh or archival).

排除标准

•Another malignancy that is progressing or has progressed within the past 3 years and/or that requires treatment. Note: Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ cervical cancer, early-stage endometrial cancer that has been definitively treated, superficial bladder cancer, Gleason 6/7 treated prostate cancer, and ductal carcinoma in situ or lobular carcinoma in situ of the breast., History or evidence of interstitial lung disease, including noninfectious pneumonitis., Presence of a GI condition that may affect drug absorption., Active autoimmune disease requiring systemic treatment, including corticosteroids exceeding a daily dose of 10 mg of prednisone or equivalent., A diagnosis of immunodeficiency or receiving chronic systemic steroid therapy exceeding a daily dose of 10 mg of prednisone or equivalent., HIV infection with a CD4+ T-cell count < 200 cells/µL and/or a detectable viral load per parameters of assay and/or on an ART regimen containing a moderate or potent CYP3A4/CYP3A5 inhibitor or inducer and/or on a new ART regimen for less than 28 days prior to the initiation of study treatment., Active infection, including tuberculosis, requiring systemic therapy, with the exception of HIV as noted in Exclusion Criterion 14., History of organ transplantation, including allogeneic stem cell transplantation., Known hypersensitivity or severe reaction to any component of study drug or formulation components., Major surgery within 4 weeks of the start of study therapy or postoperative complications preventing the participant from adhering to protocol assessments and procedures., Presence of GI conditions that may affect drug absorption, as well as those that interfere with GI transit, including gastric bypass surgery, gastric sleeve, or gastric band., CNS metastases requiring treatment and/or leptomeningeal disease. a.Participants with untreated CNS metastases that are symptomatic, who require increasing doses of steroids and/or a steroid dose of more than 1 mg of dexamethasone daily (or equivalent), or with lesions with a significant amount of surrounding edema. b.Participants with previously treated CNS metastases that are progressing, who are not clinically stable within 2 weeks of the initiation of study treatment, or who require increasing doses of steroids and/or a steroid dose of more than 1 mg of dexamethasone daily (or equivalent)., Inability to swallow tablets., Receipt of systemic antibiotics within 28 days of the first dose of study treatment., Probiotic usage during screening and throughout the study treatment period., Receipt of a live-attenuated vaccine (such as measles, mumps, and rubella; chickenpox; some zoster; yellow fever; rabies; BCG; and typhoid vaccines) within 28 days of the planned start of study drug. Note: Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines are live-attenuated vaccines and are not allowed. Note: If enrolled, participants should not receive live-attenuated vaccines during the study and up to 90 days after the last dose of study treatment (see Section 6.7.3)., Medication with any of the following characteristics that cannot be discontinued prior to the start of study treatment: moderate and potent CYP3A4/CYP3A5 inhibitors or inducers (see Appendix B), CYP3A substrates with a narrow therapeutic index, P-gp substrates with a narrow therapeutic index, inhibitors o

研究者

发起方

Incyte Corp.

相似试验

进行中（未招募）

1 期

CTIS2023-503243-34-00Incyte Corp.124

招募中

1 期

A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma

CTIS2022-502476-23-00Incyte Corp.241

终止

1 期

A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C MutationAdvanced Solid Tumors

NCT06039384Incyte Corporation6

终止

1 期

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid TumorsHepatocellular Carcinoma (HCC)Renal Cell Carcinoma (RCC)Microsatellite Instability - High (MSI-H)Mismatch Repair Deficient (dMMR)Colorectal Carcinoma (CRC)Melanoma

NCT05909995Incyte Corporation8

终止

1 期

A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid TumorsAdvanced Solid Tumors

NCT05949632Incyte Corporation5